Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Metoclopramide Injection, USP in the U.S. Market
Details : Reglan-Generic (metoclopramide) is a 5-HT3a and D2 receptor inhibitor small molecule drug candidate indicated for the treatment of diabetic gastroparesis, & prevention of nausea and vomiting.
Brand Name : Reglan-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2024
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Palonosetron Hydrochloride Injection, USP in the U.S. Market
Details : Palonosetron HCl generic of Aloxi is a 5-HT3 receptor antagonist indicated as an antiemetic in adults for prevention of acute and delayed nausea and vomiting.
Brand Name : Aloxi-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2024
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Prochlorperazine Edisylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Prochlorperazine Edisylate Injection, USP in the U.S. Market
Details : Compazine (prochlorperazine edisylate) is a D2 receptor inhibitor small molecule drug. It is indicated to control severe nausea and vomiting and for the treatment of schizophrenia.
Brand Name : Compazine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2024
Lead Product(s) : Prochlorperazine Edisylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Tranexamic Acid Injection, USP in the U.S. Market
Details : Cyklokapron-Generic (tranexamic acid) is a plasminogen inhibitor, small molecule drug candidate. which is indicated for the treatment of patients with hemophilia.
Brand Name : Cyklokapron-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2024
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isoproterenol HCl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Isoproterenol Hydrochloride Injection, USP in the U.S. Market
Details : Isuprel-Generic (isoproterenol hydrochloride) is a beta-adrenergic agonist indicated for episodes of heart block that do not require electric shock & bronchospasm.
Brand Name : Isuprel-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2024
Lead Product(s) : Isoproterenol HCl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Magnesium Sulfate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Magnesium Sulfate in Water for Injection in the U.S. Market
Details : Magnesium Sulfate in Water for Injection is a NMDA inhibitor, indicated for the prevention and control of seizures in preeclampsia and eclampsia.
Brand Name : Magnesium Sulfate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2024
Lead Product(s) : Magnesium Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Eptifibatide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Eptifibatide for Injection in the U.S. Market
Details : Integrilin-Generic (eptifibatide) is a USFDA approved platelet aggregation inhibitor, which is indicated for the treatment of patients with acute coronary syndrome.
Brand Name : Integrilin-Generic
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 29, 2024
Lead Product(s) : Eptifibatide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market
Details : The company launched desmopressin acetate for injection in the US as a therapeutic equivalent generic for DDAVP, indicated for central diabetes insipidus, hemophilia A.
Brand Name : DDAVP-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Furosemide for Injection in the U.S. Market
Details : Lasix-Generic (furosemide) is a USFDA approved loop diuretic indicated for treating edema in adults and pediatric patients with congestive heart failure, cirrhosis, and renal disease.
Brand Name : Lasix-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2024
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces New Product Launches and Participation in DCAT Week 2024
Details : Emend-Generic (fosaprepitant) is an NK1 receptor antagonist for preventing nausea and vomiting in adults and pediatric patients aged 6 months and older during chemotherapy.
Brand Name : Emend-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2024
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?